Study to Evaluate the Safety and Efficacy of Rabacfosadine, Vincristine, Cyclophosphamide, Doxorubicin and Prednisone in Dogs with Untreated Lymphoma
condition(s)
lymphoma
eligibility information
Enrollment Deadline
Enrollment ends April 6, 2022